Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hepatic Safety Of Biogen Idec’s Zinbryta Under Close Scrutiny In EU

Executive Summary

The EU review of Biogen Idec’s MS drug Zinbryta is continuing as a special group at the European Medicines Agency prepares to discuss a list of questions regarding the product’s hepatic safety profile. The EMA has until the end of November to give its views on the product’s future.


Related Content

The Zinbryta Withdrawal And The Limits Of US FDA’s Proactive Communication
Zinbryta Global Withdrawal Driven In Part By Difficulty Of Safety Assessment
Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts